Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC.
|
29782360 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Cyclooxygenase-2 over-expression was observed in 40% of normal colonic mucosa, 65% of colorectal adenoma and 84.6% of CRC cases.
|
30106414 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer.
|
30008836 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
COX-2 mRNA levels increased similarly with statistical significance in IBD and CRC.
|
30186819 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the prostaglandin-dependent pathways, inhibition of cyclooxygenase (COX), particularly COX-2, is the primary mechanism known to be involved in aspirin-induced CRC suppression.
|
29552221 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Post-translational modifications of prostaglandin-endoperoxide synthase 2 in colorectal cancer: An update.
|
30622375 |
2018 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
It has been found that the inhibitory enzyme cyclooxygenase-2 (COX-2) in the colorectal region can potentially reduce the risk of colorectal cancer.
|
29617306 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study is to investigate the relationship between the status of COX-2 expression in the primary CRC and the characteristics of recurrence after curative resection of stage I to III CRC.
|
30034467 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patient databases also delineated the correlation of RIPK3 and COX-2 expression with colorectal cancer survival.
|
30012671 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IGF-IR and COX-2 expressions were correlated to infiltration degree, lymphatic metastasis (in CRC tissues with and without Ras and BRAF mutations), and Dukes stages (only in CRC tissues with Ras and BRAF mutations).
|
28188432 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The Impact of Dietary Polyphenols on COX-2 Expression in Colorectal Cancer.
|
29068698 |
2018 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, it was concluded that NSAIDs, particularly cyclooxygenase-2 (COX-2) inhibitors, might have a protective effect on CRC development and slow down progression of tumor in a DMH-induced experimental cancer model.
|
29562216 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the other hand, NPX and other NSAIDs are extensively studied in terms of colorectal cancer (CRC) prevention and inhibition, since it has been evidenced that COX-2 corresponds with the risk of the tumor occurrence and growth.
|
28260506 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclooxygenase-2 (COX-2) plays a critical role in the development and progression of CRC.
|
28786533 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study provided the evidence towards better antiproliferative effect of AR13 and AR15 in DMH-induced CRC through the blockade of COX-2/JAK-2/STAT-3 signal transduction pathway and could be demonstrated as useful anti-CRC candidate molecules for future anticancer therapy.
|
29229353 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A mechanistic analysis revealed that YAP1 promoted CRC-derived MDSC induction by suppressing PTEN expression to up-regulate COX-2, P-AKT and P-p65 in CRC-derived cells, leading to secretion of the cytokine granulocyte-macrophage colony-stimulating factor.
|
29770434 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study suggests that meat intake may activate TLRs at the epithelial surface, leading to CRC via inflammation by nuclear transcription factor-κB-initiated transcription of inflammatory genes, whereas intake of fiber may protect against CRC via TLR4-mediated secretion of interleukin-10 and cyclooxygenase-2.
|
29566186 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Colorectal cancers exhibit a high level of cyclooxygenase-2 (COX-2) expression with strong preclinical rationale for improved clinical outcomes with COX-2 inhibition.
|
29158365 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prostaglandin E2 (PGE2), a major product of cyclooxygenase-2 (COX-2), plays an important role in the carcinogenesis of many solid tumors, including colorectal cancer.
|
30269738 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer.
|
29853736 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present review, we provide published evidence to demonstrate that (1) COX-2 signaling plays a major role in the progression of colorectal cancer, (2) activation of COX-2 in the stromal compartment also contributes to colorectal carcinogenesis, and (3) inhibition of COX-2 signaling by COX-2 inhibitors might be an effective method to control colorectal cancer.
|
27810226 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SerpinB3 upregulates the Cyclooxygenase-2 / β-Catenin positive loop in colorectal cancer.
|
28178650 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to investigate the role of FosB on the COX-2/PGE2 axis in CRC cells with high COX-2 expression levels.
|
28454270 |
2017 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Feces COX-2 mRNA has a high sensitivity for detect colorectal cancer; combination with FOBT will be the best alternative.
|
28139497 |
2017 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab.
|
28423516 |
2017 |